Novo on US senate subpoena vote: "We have repeatedly told them that Lars Fruergaard would be happy to testify"

Novo Nordisk’s country manager in the US may be called to testify on list prices at the US Senate, but the pharmaceutical firm says it has repeatedly offered them a bigger fish. 
Doug Langa, EVP and Head of American Operations at Novo Nordisk, may be issed a subpoena to appear in front of a US Senate committee. | Photo: Novo Nordisk / Pr
Doug Langa, EVP and Head of American Operations at Novo Nordisk, may be issed a subpoena to appear in front of a US Senate committee. | Photo: Novo Nordisk / Pr
by MARKETWIRE ‎

Novo Nordisk is surprised that Senate Health Committee Chairman Bernie Sanders has announced a vote to subpoena Doug Langa, Novo Nordisk’s executive vice president responsible for the US market.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Foto: Mike Blake/Reuters/Ritzau Scanpix

    Gilead Sciences CMO to leave early 2025

    For subscribers

    Further reading